^
    3ms
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P4, N=50, Recruiting, Replimune Inc. | Phase classification: P --> P4
    Phase classification
    |
    RP3 • sturlimogene erparepvec (RP2) • Tudriqev (vusolimogene oderparepvec-wtpg)
    3ms
    Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (clinicaltrials.gov)
    P2, N=174, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2028 --> Feb 2027
    Trial completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • mesna • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    3ms
    Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy (clinicaltrials.gov)
    P1, N=0, Withdrawn, Medical College of Wisconsin | N=20 --> 0 | Initiation date: Mar 2026 --> Jun 2026 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial initiation date • Trial withdrawal
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Bria-IMT (SV-BR-1-GM) • ViraferonPeg (peginterferon-α-2b)
    4ms
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    4ms
    Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study. (PubMed, Cancer Treat Res Commun)
    Both PEG and FIL demonstrate equivalent efficacy for stem cell mobilization in MM. PEG offers superior efficiency by shortening duration and reducing sessions without increasing the total economic burden.
    Retrospective data • Journal • Real-world evidence
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • Neulasta (pegfilgrastim)
    5ms
    Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors (clinicaltrials.gov)
    P2, N=132, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Neupogen (filgrastim)
    5ms
    Host Factors DDB2 and DNA Polymerase Delta Are Linked to cccDNA Persistence in Hepatitis B Virus and Occult Hepatitis B Virus-Related Hepatocellular Carcinoma. (PubMed, J Viral Hepat)
    Serum HBcrAg levels were evaluated using the iTACT-HBcrAg assay...DDB2 expression correlated with intrahepatic viral markers in both groups and with HBcrAg only in HBV-HCC. These findings suggest that DDB2 is involved in cccDNA persistence and represents potential therapeutic targets for both overt and occult HBV-related HCC.
    Journal
    |
    DDB2 (Damage Specific DNA Binding Protein 2)
    5ms
    GIM2: Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=2000, Active, not recruiting, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | Trial completion date: Dec 2025 --> Dec 2027
    Trial completion date
    |
    paclitaxel • 5-fluorouracil • cyclophosphamide • epirubicin • Neulasta (pegfilgrastim)
    5ms
    A Comparative Evaluation of Pharmacokinetics and Immunogenicity. (clinicaltrials.gov)
    P1, N=180, Completed, Kashiv BioSciences, LLC | Active, not recruiting --> Completed | Trial primary completion date: Feb 2025 --> May 2025
    Trial completion • Trial primary completion date
    5ms
    Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing (clinicaltrials.gov)
    P1, N=18, Completed, Xiamen Amoytop Biotech Co., Ltd. | Recruiting --> Completed | N=30 --> 18 | Trial primary completion date: Aug 2025 --> Jan 2026
    Trial completion • Enrollment change • Trial primary completion date
    |
    IL4 (Interleukin 4)
    5ms
    An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Yonsei University
    New trial
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Neulasta (pegfilgrastim)
    6ms
    BRIA-ABC: Combination Study of SV-BR-1-GM With Retifanlimab (clinicaltrials.gov)
    P1/2, N=36, Completed, BriaCell Therapeutics Corporation | Enrolling by invitation --> Completed | Trial completion date: Nov 2028 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    cyclophosphamide • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)